Abemaciclib vs SPH4336

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: CDK4 and CDK6 · full HR+/HER2- Metastatic Breast Cancer pipeline

Abemaciclib · Verzenio

Marketed by Eli Lilly

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Reliable signal

NCT02107703 · Phase 3 · active, not recruiting

This was a randomized, double-blind, placebo-controlled phase 3 trial of 669 women. The primary endpoint, progression-free survival, was met with a clear, statistically significant advantage for abemaciclib plus fulvestrant.

Next expected readout: December 2026 · NCT05305924 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4) (met)

Result source: NCT02107703

SPH4336

Developed by Shanghai Pharmaceuticals Holding

Phase 2/3 in HR+/HER2- Metastatic Breast Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT05860465 (registry estimate)

No aligned efficacy figure on record for this race.

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAbemaciclibSPH4336
PFS, median16.4 vs 9.3+7.1 vs placebon 446NCT02107703
11 other results
—Trial running · NCT05744687
OS, median45.8 vs 37.3+8.5 vs placebon 446NCT02107703
6 other results
—Trial running · NCT05744687
ORR35.2% vs 16.1%+19.1 vs placebon 446NCT02107703
4 other results
  • 26.3% vs 10% n 38 · Phase 1/2 · primary NCT03280563
  • 19.7% n 132 · Phase 2 · primary NCT02102490
  • 32.9% vs 13.9% 150 mg + 8 mg/kg + 500 mg · n 79 · Phase 2 · secondary NCT02675231
  • 13.9% vs 13.9% 150 mg + 8 mg/kg · n 79 · Phase 2 · secondary NCT02675231
—Trial running · NCT05744687
Clinical benefit rate72.2% vs 56.1%+16.1 vs placebon 446NCT02107703
8 other results
—Trial running · NCT05744687

PFS, median

Abemaciclib
16.4 vs 9.3+7.1 vs placebon 446NCT02107703
11 other results
SPH4336
—Trial running · NCT05744687

OS, median

Abemaciclib
45.8 vs 37.3+8.5 vs placebon 446NCT02107703
6 other results
SPH4336
—Trial running · NCT05744687

ORR

Abemaciclib
35.2% vs 16.1%+19.1 vs placebon 446NCT02107703
4 other results
  • 26.3% vs 10% n 38 · Phase 1/2 · primary NCT03280563
  • 19.7% n 132 · Phase 2 · primary NCT02102490
  • 32.9% vs 13.9% 150 mg + 8 mg/kg + 500 mg · n 79 · Phase 2 · secondary NCT02675231
  • 13.9% vs 13.9% 150 mg + 8 mg/kg · n 79 · Phase 2 · secondary NCT02675231
SPH4336
—Trial running · NCT05744687

Clinical benefit rate

Abemaciclib
72.2% vs 56.1%+16.1 vs placebon 446NCT02107703
8 other results
SPH4336
—Trial running · NCT05744687
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

SPH4336: no structured comparison results are available for HR+/HER2- Metastatic Breast Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Abemaciclib: 4 of 4 rows · SPH4336: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAbemaciclib
Dropout rate
25.6%a
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 23 more results
5.3%
NCT02102490 · Phase 2
31.7%Abemaciclib + Fulvestrant
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
21.2%Abemaciclib + NSAI
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
10.1%150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
6.3%150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
16.7%200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
8.3%200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
25%200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
—Part A Abemaciclib: HR+, HER2+ Bre
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
34.5%Part B Abemaciclib: HR+, HER2- Bre
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
33.3%Part C Abemaciclib: Surgical Resec
NCT02308020 · Phase 2 · registry result, not featured evidence
—Part D Abemaciclib: NSCLC
NCT02308020 · Phase 2 · registry result, not featured evidence
17.4%Part E Abemaciclib: Melanoma
NCT02308020 · Phase 2 · registry result, not featured evidence
—Part F: Abemaciclib HR+ Breast Can
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
17.5%
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
—a
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 23 more results
—
NCT02102490 · Phase 2
3.2%Abemaciclib + Fulvestrant
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
1.5%Abemaciclib + NSAI
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
—150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
—150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
—200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
—Part A Abemaciclib: HR+, HER2+ Bre
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
—Part B Abemaciclib: HR+, HER2- Bre
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
—Part C Abemaciclib: Surgical Resec
NCT02308020 · Phase 2 · registry result, not featured evidence
—Part D Abemaciclib: NSCLC
NCT02308020 · Phase 2 · registry result, not featured evidence
—Part E Abemaciclib: Melanoma
NCT02308020 · Phase 2 · registry result, not featured evidence
—Part F: Abemaciclib HR+ Breast Can
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
—
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
0%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
14.3%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
14.3%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
18.2%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
12.9%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
25%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
19.2%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
20%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
29.3%a
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 23 more results
25%
NCT02102490 · Phase 2
7.9%Abemaciclib + Fulvestrant
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
6.6%Abemaciclib + NSAI
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
19.5%150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
30.8%150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
12.5%200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
33.3%200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
21.7%200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
22.2%Part A Abemaciclib: HR+, HER2+ Bre
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
27.6%Part B Abemaciclib: HR+, HER2- Bre
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
33.3%Part C Abemaciclib: Surgical Resec
NCT02308020 · Phase 2 · registry result, not featured evidence
28.6%Part D Abemaciclib: NSCLC
NCT02308020 · Phase 2 · registry result, not featured evidence
17.4%Part E Abemaciclib: Melanoma
NCT02308020 · Phase 2 · registry result, not featured evidence
41.2%Part F: Abemaciclib HR+ Breast Can
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
35.9%
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
0%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
57.1%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
57.1%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
33.3%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
51.6%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
37.5%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
50%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
26.7%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
a
diarrhoea 87.1% (placebo 27.8%)
neutropenia 49.7% (placebo 3.6%)
nausea 49.4% (placebo 24.7%)
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 23 more results
diarrhoea 90.9%
nausea 67.4%
fatigue 47.7%
NCT02102490 · Phase 2
diarrhoea 28.6%
anaemia 22.2%
fatigue 20.6%
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
diarrhoea 29.9%
neutropenia 24.8%
anaemia 23.4%
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
150 mg + 8 mg/kg
diarrhoea 77.9%
fatigue 53.2%
nausea 41.6%
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
150 mg + 8 mg/kg + 500 mg
diarrhoea 79.5%
fatigue 57.7%
nausea 48.7%
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
200 mg
diarrhoea 87.5%
nausea 62.5%
anaemia 58.3%
NCT03703466 · Phase 2 · registry result, not featured evidence
200 mg
diarrhoea 91.7%
nausea 58.3%
anaemia 41.7%
NCT03703466 · Phase 2 · registry result, not featured evidence
200 mg
diarrhoea 95.7%
anaemia 47.8%
nausea 47.8%
NCT03703466 · Phase 2 · registry result, not featured evidence
diarrhoea 55.6%
fatigue 33.3%
nausea 33.3%
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 77.6%
fatigue 48.3%
nausea 44.8%
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
alanine aminotransferase increased 66.7%
anaemia 44.4%
diarrhoea 44.4%
NCT02308020 · Phase 2 · registry result, not featured evidence
diarrhoea 53.6%
fatigue 39.3%
nausea 28.6%
NCT02308020 · Phase 2 · registry result, not featured evidence
abdominal pain 21.7%
diarrhoea 21.7%
neutropenia 21.7%
NCT02308020 · Phase 2 · registry result, not featured evidence
fatigue 52.9%
nausea 41.2%
diarrhoea 35.3%
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 84.6%
fatigue 43.6%
nausea 43.6%
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
1000 mg
diarrhoea 100%
decreased appetite 66.7%
vomiting 66.7%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
anaemia 100%
diarrhoea 100%
aspartate aminotransferase increased 85.7%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
diarrhoea 85.7%
asthenia 71.4%
neutropenia 71.4%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
diarrhoea 90.9%
nausea 66.7%
neutrophil count decreased 51.5%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
diarrhoea 93.5%
nausea 67.7%
neutrophil count decreased 51.6%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
diarrhoea 100%
nausea 75%
asthenia 62.5%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
diarrhoea 61.5%
nausea 61.5%
decreased appetite 42.3%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
diarrhoea 93.3%
asthenia 60%
headache 53.3%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for 23 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Abemaciclib

PFS 8.3 vs 5.7 Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg + 500 mg
time to event · months
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 3 more results
5.7 vs 5.7 Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
16.4 vs 9.3 placebo months
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
6.28 vs 1.95 Fulvestrant months
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
Overall Survival 45.8 vs 37.25 placebo months
time to event · months
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
26.71 vs 26.02 Fulvestrant months
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
ORR 32.9% (n=79) vs 13.9% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg + 500 mg
responder rate · % of participants
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 3 more results
13.9% (n=79) vs 13.9% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
35.2% (n=446) vs 16.1% (n=223) placebo
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
26.3% (n=38) vs 10% (n=20) Fulvestrant
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
Duration of Response 12.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg + 500 mg
time to event · months
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 3 more results
9.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
NA vs 25.6 placebo months
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
13.36 vs 13.03 Fulvestrant months
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
Disease Control 78.5% (n=79) vs 67.1% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg + 500 mg
responder rate · % of participants
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
74.7% (n=79) vs 67.1% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
83% (n=446) vs 75.8% (n=223) placebo
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Clinical Benefit 58.2% (n=79) vs 38% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg + 500 mg
responder rate · % of participants
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 3 more results
45.6% (n=79) vs 38% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
72.2% (n=446) vs 56.1% (n=223) placebo
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
42.1% (n=38) vs 15% (n=20) Fulvestrant
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
ORR 19.7% (n=132)
responder rate · % of participants
No placebo or comparator arm
NCT02102490 · Phase 2
Overall Survival 22.32 months
time to event · months
No placebo or comparator arm
NCT02102490 · Phase 2
show 4 more results
10.06 months
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
13.38 months
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
7.13 months
NCT02308020 · Phase 2 · registry result, not featured evidence
2.93 months
NCT02308020 · Phase 2 · registry result, not featured evidence
Duration of Response 5.78 months1000 mg
time to event · months
No placebo or comparator arm
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
show 4 more results
4.63 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
11.12 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
17.54 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
8.6 months
NCT02102490 · Phase 2
PFS 2.1 months1000 mg
time to event · months
No placebo or comparator arm
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
show 8 more results
NA months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
13.6 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
33.1 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
6 months
NCT02102490 · Phase 2
2.07 months
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
4.41 months
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
1.45 months
NCT02308020 · Phase 2 · registry result, not featured evidence
1.22 months
NCT02308020 · Phase 2 · registry result, not featured evidence
Disease Control 67.4% (n=132)
responder rate · % of participants
No placebo or comparator arm
NCT02102490 · Phase 2
show 4 more results
40.7% (n=27)
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
51.7% (n=58)
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
39.3% (n=28)
NCT02308020 · Phase 2 · registry result, not featured evidence
26.1% (n=23)
NCT02308020 · Phase 2 · registry result, not featured evidence
Clinical Benefit 42.4% (n=132)
responder rate · % of participants
No placebo or comparator arm
NCT02102490 · Phase 2
show 4 more results
13% (n=23)
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
26.9% (n=52)
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
26.1% (n=23)
NCT02308020 · Phase 2 · registry result, not featured evidence
9.1% (n=22)
NCT02308020 · Phase 2 · registry result, not featured evidence

+ 31 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Abemaciclib's landscape · SPH4336's landscape